"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"

Condition(s) studied

Investigational drug(s) / intervention(s)

Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.: All patients will be subjected to: A- Complete medical history: including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations. B- Clinical examination: * General and local rheumatologic examination. * Local chest examination (inspection, palpation, percussion, auscultation). * Assessment of RA disease activity using DAS 28 ESR. C- Laboratory investigations: CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status. D- Radiology and PFT: PFTs and HRCT chest patterns will be done for patients. E- MMP measurement: MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays. F. The capillaroscopy procedure

Study summary

This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria.

Aim of the study

* To assess the matrix metalloproteinase 7 and 9 (MMP7,9) as a screening tool for interstitial lung disease in rheumatoid arthritis patients and to assess for correlation with RA-disease activity.
* To investigate whether certain MMPs could be potential biomarkers reflecting the lung fibrotic process in RA patients.
* To assess the capillaroscopy changes in RA and RA-ILD.
* To detect correlation between MMPs and capillaroscopic changes in RA patients. This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010 classification criteria.

The patients will be divided into 3 groups:

Group (1): RA patients with ILD. Group (2): RA patients without ILD Group (3): Healthy controls

All patients will be subjected to:

A- Complete medical history:

Detailed medical history will be taken including demographic data (age, sex, disease duration, morning stiffness, joint involvement, smoking, habits of medical importance), articular and extra articular manifestations. Detailed respiratory manifestations as (dyspnea, cough, chest wheeze, others)

B- Clinical examination:

* General and local rheumatological examination.
* Local chest examination (inspection, palpation, percussion, auscultation).
* Assessment of RA disease activity using DAS 28 ESR. Score interpretation \<2.6 suggests disease remission. 2.6-3.2 suggests low disease activity 3.2-5.1 suggests moderate disease activity \>5.1 suggest high disease activity

C- Laboratory investigations:

Peripheral venous blood samples for CBC, C-reactive protein, erythrocyte sedimentation rate, antibody status.

D- Radiology and PFT:

PFTs and HRCT chest patterns will be done for patients.

E- MMP measurement:

Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assas.

This ELISA kit uses the Sandwich-ELISA principle.

Eligibility

Primary outcome measure(s)

• 1. Creation of a statistical relation between Matrix Metalloprotienases 7 and 9 concentrations and the severity of the RA. 2. Creation of a statistical relation between MMPs concentrations and development of ILD. — at time of enrollement
  1\. Creation of a statistical relation between MMPs concentrations and the severity of the RA. 2. Creation of a statistical relation between MMPs concentrations and development of ILD. Secondary Outcome Measure

Trial sites (1)

More Assiut University trials in Egypt

Other trials for the same condition